Reversion of structure-activity relationships of antitumor platinum complexes by acetoxime but not hydroxylamine ligands.
Stefanie Zorbas-Seifried, Michael A Jakupec, Nikolay V Kukushkin, Michael Groessl, Christian G Hartinger, Olga Semenova, Haralabos Zorbas, Vadim Yu Kukushkin, Bernhard K Keppler
文献索引:Mol. Pharmacol. 71(1) , 357-65, (2007)
全文:HTML全文
摘要
The presence of cis-configured exchangeable ligands has long been considered a prerequisite for antitumor activity of platinum complexes, but over the past few years, several examples violating this structure-activity relationship have been recognized. We report here on studies with the geometric isomers of [PtCl2(acetoxime)2], cis-[dichlorobis(acetoxime)platinum(II)] [1 (cis)] and trans-[dichlorobis(acetoxime)platinum(II)] [2 (trans)], as well as those of [PtCl2(hydroxylamine)2], cis-[dichlorobis(hydroxylamine)platinum(II)] [3 (cis)] and trans-[dichlorobis(hydroxylamine)platinum(II)] [4 (trans)]. We found that 2 (trans)is 16 times more cytotoxic than 1 (cis) and as cytotoxic as cisplatin in cisplatin-sensitive ovarian carcinoma cells (CH1). Moreover, 2 (trans) is 15 times more cytotoxic than either cisplatin or 1 (cis) in intrinsically cisplatin-resistant colon carcinoma cells (SW480). Thus, compound 2 (trans) represents a novel type of active platinum(II) complexes of the trans geometry, whereas the hydroxylamine-containing complexes conform to the classic structure-activity relationships. The reactivity of the compounds toward dGMP and DNA and their capacity to alter the structure of double-stranded DNA and form interstrand cross-links were studied by capillary electrophoresis and gel electrophoresis. The slow binding of 2 (trans) to dGMP (tau(1/2) = 50 h versus 8.9 h in the case of cisplatin), the low reactivity toward DNA, the comparatively small impact on DNA secondary structure, and the lack of detectable interstrand cross-linking suggest a mode of action fundamentally different from that of cisplatin. Implications of our findings for the minimal structural requirements (e.g., planarity around the nitrogen donor atom and/or ramified aliphatic moiety attached to the latter) of active trans-configured platinum complexes are discussed.
相关化合物
相关文献:
1999-02-01
[Toxicol. Sci. 47(2) , 144-50, (1999)]
2014-01-01
[Chem. Pharm. Bull. 62(9) , 898-905, (2014)]
1997-12-01
[Chem. Res. Toxicol. 10(12) , 1420-6, (1997)]
1990-09-01
[Carcinogenesis 11(9) , 1659-62, (1990)]
1990-06-01
[Carcinogenesis 11(6) , 1013-6, (1990)]